<DOC>
	<DOCNO>NCT00458601</DOCNO>
	<brief_summary>This study design evaluate clinical activity CDX-110 vaccination give standard care treatment ( maintenance temozolomide therapy ) . Study treatment give disease progression patient follow long-term survival information . Efficacy measure progression-free survival status 5.5 month date first dose .</brief_summary>
	<brief_title>Phase II Study Rindopepimut ( CDX-110 ) Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Newly diagnose de novo GBM document EGFRvIII expression tumor tissue . Gross total resection follow conventional chemoradiation therapy without progression disease . Presence diffuse leptomeningeal disease gliomatosis cerebri . Systemic corticosteroid therapy &gt; 2 mg dexamethasone equivalent ( defined investigator ) per day study enrollment . Patients undergone stereotactic radiosurgery prior follow surgical resection , placement GliadelÂ® Wafers . Known allergy hypersensitivity KLH , GMCSF yeast derive product , history anaphylactic reaction shellfish protein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>EGFRvIII vaccinetemozolomidecancer vaccineimmunotherapy</keyword>
</DOC>